Find research datasets worth reusing

opencc-zeroJun 2020View details →

Data from: Headache after ischemic stroke: a systematic review and meta-analysis

Objective: Headache associated with ischemic stroke is poorly understood. To gain further insight, we systematically reviewed studies examining the prevalence and characteristics of new onset post-stroke headache. Methods: Medline and PubMed databases were queried. 1812 articles were identified. Of these, 50 were included in this systematic review. Twenty were included in a meta-analysis and meta-regression. Results: Headache occurred in 6-44% of the ischemic stroke population. Most headaches had tension-type features, were moderate to severe and became chronic in nature. Meta-analysis using an inverse-variance heterogeneity model revealed a pooled prevalence of 0.14 (95%CI 0.07 – 0.23) with heterogeneity among studies. Meta-regression revealed a significant association between prevalence and study location, the source population's national human development index (HDI), and study quality. We found higher prevalence in European (0.22, 95%CI 0.14 – 0.30) and North American (0.15, 95% CI 0.05 – 0.26) studies compared with Middle eastern and Asian studies (0.08, 95% CI 0.01 – 0.18). However, within each region, populations from countries with higher HDI (p=0.03) and studies with higher quality (p=0.001) had lower prevalence. Calculated crude odds ratios showed that posterior circulation stroke (pooled OR 1.92, 95%CI 1.4-2.64; n=7 studies) and female sex (pooled OR 1.25, 95%CI 1.07-1.46; n=11 studies) had greater odds of headache associated with ischemic stroke. Conclusions: Taken together, these data suggest that headache is common at the onset of or shortly following ischemic stroke and may contribute to post-stroke morbidity. Better understanding of headache associated with ischemic stroke is needed to establish treatment guidelines and inform patient management.

opencc-zeroOct 2020View details →

Data from: Safety and efficacy of dual antiplatelet pretreatment in ischemic stroke patients treated with intravenous thrombolysis: a systematic review and meta-analysis

Objective: Conflicting data exist regarding the safety and efficacy of IV thrombolysis (IVT) in acute ischemic stroke (AIS) patients receiving dual antiplatelet pretreatment (DAPP). The aim of the present systematic review and meta-analysis is to assess the safety and outcome of DAPP history among AIS patients treated with IVT. Methods: We performed a comprehensive literature review to identify studies that investigated the safety and efficacy of DAPP among AIS patients treated with IVT. Results: We identified 9 studies comprising 66,675 patients. In unadjusted analyses, DAPP was associated with higher likelihood of pooled symptomatic intracranial hemorrhage (sICH, OR = 2.26, 95% CI 1.39–3.67) and 3-month mortality (OR = 1.47, 95% CI 1.27–1.73). DAPP was also related to higher odds of sICH according to SITS-MOST (OR = 2.71, 95% CI 2.05–3.59), ECASS II (OR=2.23, 95% CI 1.46–3.40) and NINDS (OR=1.59, 95% CI 1.38–1.83) definitions. There was no association between DAPP and 3-month favorable functional outcome (FFO, mRS 0-1), and 3-month functional independence (FI, mRS 0-2). In adjusted analyses, history of DAPP was not associated with pooled sICH (OR=2.03, 95% CI 0.75–5.25), 3-month mortality (OR=1.11, 95% CI 0.87–1.40), 3-month FFO (OR=0.92, 95% CI 0.77–1.09), and 3-month FI (OR=1.01, 95% CI 0.89–1.15). Conclusions: After adjustment for potential confounders DAPP appears not to be associated with higher risk of adverse outcomes in AIS patients treated with IVT.

opencc-zeroOct 2020View details →

Data from: Interaction of serum vitamin B12 and folate with MTHFR genotypes on risk of ischemic stroke

Abstract Objective We evaluated the interaction of serum folate and vitamin B12 (B12) with methylenetetrahydrofolate reductase (MTHFR) C677T genotypes, on the risk of first ischemic stroke, and on the efficacy of folic acid (FA) treatment in prevention of first ischemic stroke. Methods A total of 20,702 hypertensive adults were randomized to a double-blind treatment of daily enalapril 10mg and FA 0.8mg or enalapril 10mg alone. Participants were followed-up every three months. Results Median values of folate and B12 concentrations at baseline were 8.1 ng/mL and 280.2 pmol/L, respectively. Over a median of 4.5 years, among those not receiving FA, participants with baseline serum B12 and/or serum folate above the median had a significantly lower risk of first ischemic stroke (HR, 0.74; 95%CI: 0.57-0.96), especially in those with MTHFR 677 CC genotype (wild type) (HR, 0.49; 95%CI: 0.31-0.78). FA treatment significantly reduced the risk of first ischemic stroke in participants with both folate and B12 below the median (2.3% in enalapril-folic acid group vs. 3.6% in enalapril-only group; HR, 0.62; 95%CI: 0.46-0.86), particularly in MTHFR 677 CC carriers (1.6% vs. 4.9%; HR, 0.24; 95%CI: 0.11-0.55). However, carriers of TT responded better with both folate and B12 levels above the median (HR, 0.28; 95%CI: 0.10-0.75). Conclusions The risk of first ischemic stroke was significantly higher in hypertensive patients with low levels of both folate and B12. Effect of FA treatment was greatest in patients with low folate and B12 with the CC genotype, and with high folate and B12 with the TT genotype.

openFeb 2024View details →

The role of a mammalian network in regulating ischemic stroke outcome

QUICK GUIDE ABOUT THE FOLDERS AND FILES This repository contains the code used to align the sequences and to analyse the counts used in the paper: The role of a mammalian network in regulating ischemic stroke outcome. Plus, it has intermediary files regarding steps of data processing. For example, the output files produced with fastqc, multiqc, PCA and other methods. The raw fastq files of the aligned sequences can be downloaded from GEO database using the links provided in the publication. "Alignments" folder contains the code used to align and quantify the sequencing data.  Each subfolder is associated to a specific sequencing dataset used in the paper. For miRNA and total RNA sequences, we used the corresponding nf-core pipeline. For circular sequences, we used ciriquant software pulled into a local docker. For each run of nf-core pipeline and ciriquant, we kept the most important intermediary files like the ones related to quality control from "fastqc" and "multiqc". For each run of nf-core pipeline, the subfolder "pipeline_info" contains the report of the execution of the nf-core pipeline and the command used to call it. For ciriquant run, config.yml and op0_CIRIquant.sh show which has been the setting and files used for the execution. The alignment of total RNA sequencing data has been performed twice. Standard alignment with default parameters. Edited_genome alignment with the mm10 genome annotation modified to include Cdr1as. Mus_musculus folder contains the mm10 genome annotation modified to include Cdr1as. "Analysis" folder contains the code to analyse the counts produced with the nf-core and ciriquant pipelines. Each subfolder is associated to a specific sequencing dataset used in the paper. The scripts of a folder are always indipendent from the files belonging to other folders. The scripts are ordered based on how they must be executed, so op1, op2, op3 ... The scripts always elaborate the data coming from their "data" folder, use the functions inside their own "funs" folder and produce the results in their own "output" folder; changing the structure of a folder may give errors during the execution of a script. "Analysis_revision" folder contains the code to add to the "Analysis" folder. This code has been added to reply to reviewer's comments. BE CAREFULL: both the code for the alignments and analysis includes pointers to file paths which must be changed in order to be run in your system.

opencc-by-4.0Apr 2024View details →

Raw Data: Enhancing Stroke Risk Prediction in Patients with Transient Ischemic Attack: Insights from a Prospective Cohort Study Implementing Fast-Track Care

Background and aims: Fast-track care have been proved to reduce the short-term risk of stroke after transient ischemic attack (TIA). We aimed to investigate stroke risk and to characterize short-and long-term stroke predictors in a large cohort of TIA patients undergoing fast-track management.Methods: Prospective study, enrolling consecutive TIA patients admitted to a Northern Italy emergency department from August 2010 to December 2017. All patients underwent fasttrack care within 24 hours of admission. The primary outcome was defined as the first stroke recurrence at 90 days, 12 and 60 months after TIA. Stroke incidence with 95% confidence interval (CI) at each timepoint was calculated using Poisson regression. Predictors of stroke recurrence were evaluated with Cox regression analysis. The number needed to treat (NNT) of fast-track care in preventing 90-day stroke recurrence in respect to the estimates based on baseline ABCD2 score was also calculated.We enrolled 1035 patients (54.2% males). Stroke incidence was low throughout the follow-up with rates of 2.2% [95% CI 1.4%-3.3%] at 90 days, 2.9% [95% CI 1.9%-4.2%] at 12 months and 7.1% [95% CI 5.4%-9.0%] at 60 months. Multiple TIA, speech disturbances and presence of ischemic lesion at neuroimaging predicted stroke recurrence at each timepoint. Male sex and increasing age predicted 90-day and 60-month stroke risk, respectively. Hypertension was associated with higher 12-month and 60-month stroke risk.No specific TIA etiology predicted higher stroke risk throughout the follow-up. The NNT for fast-track care in preventing 90-day stroke was ] in the overall cohort and 6.8 [95% CI 4.6-13.5] in patients with baseline ABCD2 of 6 to 7.Our findings support the effectiveness of fast-track care in preventing both short-and long-term stroke recurrence after TIA.

embargoedcc-by-4.0Jul 2025View details →

Raw MRI imaging for "In Vivo Neuroprotection in Ischemic Stroke by Activated Protein C Requires β-Arrestin 2"

The protease, activated protein C (APC) and its variants provide pharmacological benefits in many murine preclinical injury models, including neuroprotection for ischemic stroke and mortality reduction for sepsis.  The in vivo mechanism of action for APC in ischemic stroke and sepsis injury models, similar to extensive in vitro studies using cultured cells, involves protease activated receptor (PAR) 1-mediated biased signaling. Cell culture studies showed that APC/PAR1 signaling requires β-Arrestin 2, an intracellular scaffold protein, and that β-Arrestin 2-dependent, APC-initiated signaling can distinctly alter a wide variety of intracellular signaling pathways.  It is unclear whether in vitro studies can be extrapolated to in vivo mechanisms of action.  This study employed a proximal transient Middle Cerebral Artery Occlusion model to study the neuroprotective actions of the signaling-selective APC variant, 3K3A-APC, in β-arrestin 2 deficient (Arrb2-/-) mice. Based on the size and shape of brain injury areas, 3K3A-APC significantly limited brain injury in control mice to a relatively small, localized area whereas these protective effects were lost in Arrb2-/- mice. Thus, these data indicate that the major in vitro mechanism of action that requires β-arrestin 2 for APC/PAR1 biased signaling is central to the in vivo mechanism of action for APC’s neuroprotection.

opencc-zeroDec 2018View details →

Data from: WMH and long-term outcomes in ischemic stroke: a systematic review and meta-analysis

OBJECTIVE: To investigate the relationship between baseline white matter hyperintensities (WMH) in patients with ischemic stroke and long-term risk of dementia, functional impairment, recurrent stroke, and mortality. METHODS: Following the MOOSE and PRISMA guidelines (PROSPERO protocol: CRD42018092857), we systematically searched Medline and Scopus for cohort studies of ischemic stroke patients examining whether MRI- or CT-assessed WMH at baseline are associated with dementia, functional impairment, recurrent stroke, and mortality at 3 months or later post-stroke. We extracted data and evaluated study quality with the Newcastle-Ottawa scale. We pooled relative risks (RR) for the presence and severity of WMH using random-effects models. RESULTS: We included 104 studies with 71,298 ischemic stroke patients. Moderate/severe WMH at baseline were associated with increased risk of dementia (RR: 2.17, 95%CI: 1.72-2.73), cognitive impairment (RR: 2.29, 95%CI: 1.48-3.54), functional impairment (RR: 2.21, 95%CI: 1.83-2.67), any recurrent stroke (RR: 1.65, 95%CI: 1.36-2.01), recurrent ischemic stroke (RR: 1.90, 95%CI: 1.26-2.88), all-cause mortality (RR: 1.72, 95%CI: 1.47-2.01), and cardiovascular mortality (RR: 2.02, 95%CI: 1.44-2.83). The associations followed dose-response patterns for WMH severity and were consistent for both MRI- and CT-defined WMH. The results remained stable in sensitivity analyses adjusting for age, stroke severity, and cardiovascular risk factors, in analyses of studies scoring high in quality, and in analyses adjusted for publication bias. CONCLUSIONS: Presence and severity of WMH are associated with substantially increased risk of dementia, functional impairment, stroke recurrence, and mortality after ischemic stroke. WMH may aid clinical prognostication and the planning of future clinical trials.

restrictedcc-by-4.0Oct 2023View details →

Epidemiological and clinical characteristics of a Hungarian subpopulation of acute ischemic stroke patients

A compilation of epidemiological and clinical data as well as factors influencing therapeutic decisions in a subpopulation of acute ischemic stroke patients, who were first evaluated and/or treated at County Hospital Fejér, Szent György Hospital, Székesfehérvár, Hungary, in the period between 1 July 2022 and 28 February 2023.

Platelet Function in Patients With Ischemic Stroke Treated With Anti-thrombotic or Thrombolytic

ClinicalTrials.gov study NCT05415150. IPD Sharing: Not stated. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →

Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis

ClinicalTrials.gov study NCT05476991. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →

Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)

ClinicalTrials.gov study NCT06226805. IPD Sharing: NO. Countries: 3. Publications: 0.

The Effect of Positional Device on the Obstructive Sleep Apnea in Patients With Ischemic Stroke

ClinicalTrials.gov study NCT01699139. IPD Sharing: Not stated. Countries: 1. Publications: 0.

Clinical Trial to Evaluate the Safety of Continuous IV Tirofiban in Acute Ischemic Stroke

ClinicalTrials.gov study NCT04818944. IPD Sharing: Not stated. Countries: 1. Publications: 0.

The Association Between Obesity-Related Indicators and Adverse Outcomes in Ischemic Stroke Patients

ClinicalTrials.gov study NCT06165107. IPD Sharing: Not stated. Countries: 1. Publications: 0.

A Clinical Study on Ozone Autohemotherapy for the Treatment of Acute Ischemic Stroke

ClinicalTrials.gov study NCT06525792. IPD Sharing: Not stated. Countries: 1. Publications: 0.

Efficacy and Safety of Endovascular Thrombectomy in Acute Ischemic Stroke With Posterior Circulation Large Infarct

ClinicalTrials.gov study NCT06924996. IPD Sharing: Not stated. Countries: 1. Publications: 0.

controlledIPD-YESFeb 2026View details →

EmboTrap ® II Revascularization Device (Neuravi) in Acute Ischemic Stroke

ClinicalTrials.gov study NCT03601702. IPD Sharing: YES. Countries: 1. Publications: 0.

"Cognitive, Motor and Sleep Evaluation in Patients With Ischemic Stroke of Basal Ganglia After Thrombectomy"

ClinicalTrials.gov study NCT05878002. IPD Sharing: Not stated. Countries: 1. Publications: 0.

Cognitive Changes and Rehabilitation in People With Transient Ischemic Attack, Stroke, or Stroke Risk Factors

ClinicalTrials.gov study NCT01951612. IPD Sharing: Not stated. Countries: 1. Publications: 0.